CClinicalTrials.gg
RecruitingNCT07491653GO-FARUpdated Jun 1, 2026

Fiber mHealth Intervention for Prediabetes

An interventional study of GO-FAR in Prediabetes, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by University of Oklahoma · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 39 Years
Sex
All
01

Study summary

This is a single-arm feasibility trial to examine an mHealth intervention that combines high fiber education, home-delivered high fiber foods, and use of continuous glucose monitors.

Read the detailed description

This is a single-arm trial enrolling young adults (aged 18-39) with prediabetes (based on hemoglobin A1c). Enrolled individuals will complete baseline data collection in person to assess insulin resistance (venous blood samples). Enrolled individuals will then complete a three-month fully-mHealth based intervention focused exclusively on promoting greater fiber intake. Participants will receive weekly home-delivered shipments of high fiber foods and wear a continuous glucose monitor at two time points as a form of biofeedback. After the three months, participants will return for repeat assessment of insulin resistance. After that repeat assessment, participants will do a one-month observation period using cell phone-based ecological momentary assessments.

02

Conditions studied

  • Prediabetes

Keywords

  • Diet
  • Young adults
  • Fiber
  • Diabetes
03

In context

Prediabetic State

999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.

This study's planned enrollment of 80 is above the median of 65 across 844 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

University of Oklahoma is the lead sponsor of 424 studies on the registry; 99 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Pre-diabetes based on HbA1c
  • Young adult, aged 18-39 years
  • Reside near Tulsa metro area
  • Ability to access/use a compatible smartphone
  • Proficient in English

Exclusion criteria

Exclusion Criteria:

  • Suspected eating disorder
  • Current glucagon-like peptide-1 receptor agonist use
  • Food allergies or intolerances
  • Currently pregnant or breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Fiber-focused intervention

    Mobile phone delivered content about fiber (daily), continuous glucose monitors, and home delivered high fiber foods

    Behavioral: GO-FAR

Interventions

  • BehavioralGO-FAR

    3-month intervention combining multiple behavior change techniques (biofeedback, adding objects to the environment, instruction on how to perform the behavior), all focused on helping people at more fiber.

06

What researchers measure

Primary outcomes

  1. Recruitment (as a measure of intervention feasibility)

    Percentage of recruitment goal reached.

    Time frame: Evaluated at the end of the project period (2 years in total)

  2. Retention of participants (as a measure of feasibility)

    Percentage of enrolled participants who remain in the study throughout the intervention period

    Time frame: Retention will be based on time retained in the study over a period of approximately 5 months (from enrollment to completion of follow-up data collection)

  3. Acceptability (as a measure of feasibility)

    Participants will rate their perceived acceptability of the intervention using a 5-point Likert scale question ("How would you rate this study intervention as a whole?" rated as Poor, Fair, Good, Very Good, Excellent.

    Time frame: Measured at the end of the 3-month intervention

Secondary outcomes

  1. Dietary fiber intake

    Measured using the automated self-administered 24-hour recall

    Time frame: Baseline, after-intervention (3-months), and after a 4-week observation period

  2. Glycemic control (hemoglobin A1c [HbA1c])

    Measured via point-of-care testing devices

    Time frame: Baseline and after the intervention (3 months)

  3. Insulin resistance (Homeostatic Model Assessment of Insulin Resistance [HOMA-IR])

    Measured via venous blood samples

    Time frame: Baseline and after-intervention (3 months)

07

Study locations

1 of 1 sites recruiting
  • University of Oklahoma Health Campus
    Tulsa, Oklahoma 74135, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07491653
Lead sponsor
University of Oklahoma
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Aug 2026 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Jun 1, 2026

Study contacts

Ashlea Braun, PhD
Contact
Ashlea-Braun@ou.edu
918.660.3080
Ashlea Braun, PhD
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion